Accent Therapeutics (United States)

Recent papers from Accent Therapeutics (United States)

1. Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in RabbitsNucleic Acid Therapeutics · 2026
2. Model-optimized bispecific antibodies improve the selectivity of antibody–drug conjugates for tumorsAcademia Drug Development and Pharmacotherapy · 2026
3. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II TrialJournal of Clinical Oncology · 2026
4. Characterization of the Sequence of Cytopenia after Total-body Irradiation using Unsupervised Machine LearningRadiation Research · 2026
5. A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.Journal of Clinical Oncology · 2026
6. A BRRF1-CCR4-NOT axis underlies conserved transcriptome-wide loss of splicing fidelity during gammaherpesvirus reactivation2026
7. D107-03 Novel Interleukin-15 Superagonist (n-803) and Invariant Natural Killer T Cell (agent-797) Combination Immunotherapy for Unresolving Coccidioides Immitis InfectionAmerican Journal of Respiratory and Critical Care Medicine · 2026
8. Abstract LB056: Inhibiting WEE1 kinase enhances sensitivity of high grade serous ovarian cancer cells to the novel KIF18A inhibitor ATX020Cancer Research · 2026
9. Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapyClinical Immunology Communications · 2026
10. Abstract 5744: Robust anti-tumor activity of the novel KIF18A inhibitor, ATX-295, in preclinical models of chromosomally instable tumorsCancer Research · 2026
11. DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancersMolecular Cancer Therapeutics · 2026
12. Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial.Journal of Clinical Oncology · 2026
13. Decoding the mechanophysiology for inhaled onset of smallpox with model-based implications for mpox spreadScientific Reports · 2025
14. The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer CellsCells · 2025
15. The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor ImmunityCancer Immunology Research · 2025
16. Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom ReplacementACS Medicinal Chemistry Letters · 2025
17. Abstract B024: Investigating a novel KIF18A inhibitor ATX020 in chromosomally instable ovarian cancerCancer Research · 2025
18. Abstract A031: DHX9 inhibition induces genomic instability and enhances paclitaxel sensitivity in drug-resistant high-grade serous ovarian cancer (HGSOC) cellsCancer Research · 2025
19. Reproxalap Improves Ocular Redness, Tear Production, and Symptoms in a Pivotal Dry Eye Disease Chamber TrialOphthalmology Science · 2025
20. Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9Journal of Medicinal Chemistry · 2025